Please ensure Javascript is enabled for purposes of website accessibility

Why Mesoblast Limited Is Rising Today

By Prosper Junior Bakiny - Feb 11, 2021 at 1:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of its pipeline candidates achieved great results in a late-stage clinical study.

What happened?

On Thursday morning, biotech company Mesoblast Limited (MESO 2.27%) released data from a phase 3 clinical trial for one of its leading pipeline candidates, rexlemestrocel-L. Investors seem to be impressed with this data since the company's shares are rising sharply as a result. As of 1:25 p.m. EST, Mesoblast Limited's stock was up by 8.7%, after jumping by as much as 18% earlier today.

So what

In a phase 3 clinical trial that enrolled more than 400 patients with chronic low back pain due to degenerative disc disease (DDD), a single injection of rexlemestrocel-L reduced low back pain significantly for at least two years. The best results were obtained when the treatment was administered early in the disease process. These results indicate that rexlemestrocel-L may provide a non-opioid alternative for those suffering from low back pain due to DDD. Of note, chronic low back pain accounts for 50% of opioid prescriptions, and amid an ongoing opioid crisis, regulators are actively looking for substitute therapies.

Doctor giving a thumbs up.

Image source: Getty Images.

Now what

According to Mesoblast Limited, more than 30 million people in the U.S. suffer from low back pain; DDD is one of the leading causes of this condition. What's more, there are few treatment options for patients dealing with chronic low back pain. Today's results are therefore great news for the healthcare company and its shareholders. If rexlemestrocel-L goes on to receive the regulatory green light in this indication, it will likely experience a smashing success in the market.

It is also worth noting that last month, Mesoblast Limited reported results from a phase 3 trial that showed that a single dose of rexlemestrocel-L reduced heart attacks and strokes in patients suffering from chronic heart failure. Both of these opportunities could turn rexlemestrocel-L into a cash cow for Mesoblast Limited. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mesoblast Limited Stock Quote
Mesoblast Limited
MESO
$3.61 (2.27%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.